Moderna will share its Q3 earnings on November 6, with analysts predicting a $1.25 loss per share.

Nov 6, 2026, 2:28 AM ETResultsRead the original at Benzinga

Bad for MRNA

Analysts expect a bigger quarterly loss and lower sales than a year earlier, pointing to weaker results. Canada's approval of 2 vaccines for adults 50 and older is positive, but the article gives no sales estimate from them.

MRNA · Moderna, Inc.

AI read · Bad for MRNA

The AI's read

The estimates point to a weaker quarter. Canada's approval of mFLUSIVA and mCOFLU for adults 50 and older is a plus, but the story gives no expected sales from those vaccines. Analyst views were mixed, with one downgrade alongside several raised price targets.

Get alerts for MRNA

Follow Moderna, Inc. (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MRNA

Free on the App Store and Google Play, or on the web.